An interim, blinded safety analysis from ProMIS Neurosciences’ amyloid-targeting Alzheimer’s candidate was reported with low brain bleeding and limited swelling signals. The company said the pooled rate of ARIA was 4.4%, with reported cases described as mild and asymptomatic, and with no incidences of ARIA-E in the interim dataset. While the prompt excerpt does not provide efficacy outcomes, the signal is positioned as potentially differentiating on tolerability compared with approved anti-amyloid therapies that have shown ARIA burdens. Safety data were framed as supporting a possible path toward continued clinical development. The report adds to the competitive focus on balancing amyloid engagement with risk mitigation in trials that increasingly emphasize MRI-monitorable adverse effects early in development.